PerkinElmer and the European Molecular Biology Laboratory (EMBL) Announce Corporate Partnership to Support EMBL Advanced Training Centre

PerkinElmer, Inc., a global leader in life science research, drug discovery and cellular science, and the European Molecular Biology Laboratory (EMBL) today announced that they have entered into a corporate partnership in support of the EMBL’s Advanced Training Centre in Heidelberg, Germany.

Under the terms of the partnership, PerkinElmer will sponsor and have access to the Advanced Training Centre’s center of excellence for molecular biology training in Europe, including scientific training programs, facilities, conferences and events. PerkinElmer will also provide advice regarding future conferences and programs at the Centre.

The recently established EMBL Corporate Partnership Program is designed to create and enhance long-term, effective relationships between EMBL and top-tier corporate partners.

Professor Iain Mattaj, EMBL director general, said, "Our organization is delighted to have a partner of PerkinElmer’s caliber in promoting the mission of EMBL and supporting the aims of the Advanced Training Centre. This partnership is a significant milestone in our shared vision to create a central platform for training and exchange in molecular biology in Europe. We look forward to inaugurating the state-of-the-art Centre when it is completed in 2009.”

Richard M. Eglen, Ph.D., president, Bio-discovery, PerkinElmer, said, "PerkinElmer is glad to participate in advancing one of the most active advanced training and conference centers in Europe for molecular and cellular sciences. International collaborations will be the key to future successes and breakthroughs in the field, and our work with EMBL toward this end is a very welcome step in this direction.”

About EMBL

The European Molecular Biology Laboratory is a basic research institute funded by public research monies from 20 member states (Austria, Belgium, Croatia, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden, Switzerland and the United Kingdom) and associate member state Australia. Research at EMBL is conducted by approximately 80 independent groups covering the spectrum of molecular biology. The Laboratory has five units: the main Laboratory in Heidelberg, and Outstations in Hinxton (the European Bioinformatics Institute), Grenoble, Hamburg, and Monterotondo near Rome. The cornerstones of EMBL’s mission are: to perform basic research in molecular biology; to train scientists, students and visitors at all levels; to offer vital services to scientists in the member states; to develop new instruments and methods in the life sciences and to actively engage in technology transfer activities. EMBL’s International PhD Programme has a student body of about 170. The Laboratory also sponsors an active Science and Society programme. Visitors from the press and public are welcome.

For more information, please visit our website at www.embl.de.

About PerkinElmer Bio-discovery

PerkinElmer's Bio-discovery business provides the most comprehensive offering of enabling technologies and services including biochemistry, detection systems, cell imaging, and liquid handling to accelerate life sciences research, from drug discovery to academic research.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and their environment. The Company reported revenue of $1.8 billion in 2007, has approximately 9,100 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

Effective January 1, 2009, PerkinElmer will begin operating within two businesses—Human Health and Environmental Health. In the interim, PerkinElmer will continue to operate as two business units—Life and Analytical Sciences and Optoelectronics.